Clinical Trial Update: Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of Sacituzumab Govitecan and Anlotinib in previously treated extensive-stage small cell lung cancer; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: China Medical University, China | Conditions: Extensive-Stage Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING